SCHEMBL958145

SCHEMBL958145

COc1ccc(-c2ccc(S(=O)(=O)NC(C)(C)C)cc2C)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 3/20 0.47
PIK3CD O00329 2/20 0.44
PIK3CG P48736 1/20 0.44
CYP2A6 P11509 1/20 0.44
PARG Q86W56 1/20 0.44
PTGES2 Q9H7Z7 1/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
USP2 O75604 2/20 0.43
TP53 P04637 1/20 0.43
MAPT P10636 1/20 0.43
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ALOX5AP P20292 2/20 0.42
FEN1 P39748 2/20 0.42
PIK3R2 O00459 1/20 0.42
PIK3R1 P27986 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL956944 0.83 FBP1 (0.56) PIK3CDPIK3CGCYP2A6PARGALOX5AP
SCHEMBL958258 0.81 CA1 (0.57) KCNH2CYP2A6PTGES2OXTRAVPR2
SCHEMBL24549313 0.80 ALDH1A1 (0.49) PARGMEN1KMT2AUSP2MAPT
SCHEMBL957757 0.73 FBP1 (0.77) FBP1
SCHEMBL958259 0.73 PARG (0.46) PIK3CDPIK3CGPARGMEN1KMT2A
SCHEMBL15959129 0.72 CYP2A6 (0.45) KCNH2CYP2A6OXTRAVPR2AVPR1A
SCHEMBL15959127 0.72 HSD17B1 (0.59) CYP2A6
SCHEMBL10094614 0.67 CYP2A6 (0.61) CYP2A6OXTRAVPR2AVPR1AJAK2
SCHEMBL2224770 0.67 KCNH2 (0.76) KCNH2
SCHEMBL12932731 0.66 SMN1; SMN2 (0.61) MEN1KMT2ATP53MAPTALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868030-B2 FBPase inhibitors for diabetes HOFFMANN-LA ROCHE INC. (US) 2011-01-11 US disclosed
EP-2032548-A1 THIAZOLE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2009-03-11 EP disclosed
WO-2007137962-A1 THIAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-12-06 WO disclosed
US-20070281979-A1 Fructose-1,6-bisphosphatase (FBPase) inhibitors, such as N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]3(difluoromethoxy)benzenesulfonamide, used as antidiabetic agents HOFFMANN-LA ROCHE INC. 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281979-A1 Fructose-1,6-bisphosphatase (FBPase) inhibitors, such as N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]3(difluoromethoxy)benzenesulfonamide, used as antidiabetic agents FBP1, PFKFB1, PFKFB3 KCNH2 3035/4885PIK3CD 1753/4885PIK3CG 1517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.